New combo shows promise for tough breast cancer
NCT ID NCT04603183
First seen Jan 11, 2026 · Last updated May 23, 2026 · Updated 17 times
Summary
This study tested two treatment plans for people with advanced HR+/HER2- breast cancer that is aggressive. One group got a drug called abemaciclib plus hormone therapy, while the other group started with chemo followed by the same combo. The goal was to see which approach works better at shrinking tumors in the first 12 weeks. The trial included 162 adults and is now complete.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER METASTATIC are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Azienda Ospedaliero-Universitaria Cittá de la Salute e della Scienza
Torino, 10126, Italy
-
Centro Oncoloxico de Galicia
A Coruña, Coruña, 15009, Spain
-
Complejo Asistencial Universitario De León
León, Leon, 24073, Spain
-
Complejo Hospitalario de Navarra
Pamplona, Pamplona/Iruña, 31008, Spain
-
Consorcio Hospital General Universitario de Valencia
Valencia, 46014, Spain
-
Consorcio Hospitalario Provincial de Castellon
Castellon, 12002, Spain
-
Fundación Althaia Manresa
Manresa, Barcelona, 08243, Spain
-
Hospital Arnau de Vilanova
Valencia, 46015, Spain
-
Hospital Beata María Ana
Madrid, 28007, Spain
-
Hospital Clinico Universitario de Valencia
Valencia, 46010, Spain
-
Hospital Fernando da Fonseca
Amadora, 2720-276, Portugal
-
Hospital General Universitario de Alicante
Alicante, 03010, Spain
-
Hospital Quiron Salud Dexeus
Barcelona, Spain
-
Hospital Quironsalud Valencia
Valencia, 460137, Spain
-
Hospital Quirónsalud Sagrado Corazón
Seville, 41013, Spain
-
Hospital Ruber Juan Bravo
Madrid, 28006, Spain
-
Hospital Universitari de Sant Joan de Reus
Reus, Tarragona, 43204, Spain
-
Hospital Universitario Arnau de Vilanova
Lleida, 25198, Spain
-
Hospital Universitario Basurto
Bilbao, 48013, Spain
-
Hospital Universitario Clinico San Carlos
Madrid, 28040, Spain
-
Hospital Universitario La Paz
Madrid, 28046, Spain
-
Hospital Universitario Miguel Servet
Zaragoza, 50009, Spain
-
Hospital Universitario Ramón y Cajal
Madrid, 28034, Spain
-
Hospital Universitario Reina Sofia
Córdoba, Cordoba, 14004, Spain
-
Hospital Universitario San Cecilio
Granada, 18016, Spain
-
Hospital Universitario Virgen del Rocio
Seville, Andalusia, Spain
-
Hospital de Santa Maria - Centro Hospitalar Lisboa Norte
Lisbon, 1600-190, Portugal
-
Institut Catala D'Oncologia Girona - Hospital Josep Trueta
Girona, 17007, Spain
-
Instituto Europeo di Oncologia
Milan, 20141, Italy
-
Ospedale Guglielmo da Saliceto
Piacenza, 29121, Italy
-
Ospedale San Gerardo
Monza, 20900, Italy
Conditions
Explore the condition pages connected to this study.